Limited Impact of Adjuvant Chemotherapy in ALK-Positive Stage II-III Lung Adenocarcinoma: A Multicenter CReGYT-03 ALK Study.
Akira Hamada
Shinkichi Takamori
Asato Hashinokuchi
M. Shimokawa
K. Suda
S. Katsumata
N. Haratake
Kotaro Nomura
Yoshihisa Shimada
T. Toyoda
Takuya Watanabe
K. Hayasaka
Masaoki Ito
S. Ohara
S. Fukuda
Tomoyo Fukami
H. Oiki
K. Minegishi
Kantaro Hara
Mao Yoshikawa
Ken Suzawa
K. Shien
Kosuke Fujino
Takamasa Koga
K. Kosai
A. Kamigaichi
H. Notsuda
Taichi Matsubara
S. Tane
M. Abe
Somei Matsuo
Sho Wakasu
S. Muto
Satoru Okada
T. Nishimura
M. Toda
Makoto Endo
Kazuki Takada
K. Sekihara
Jun Suzuki
Hikaru Watanabe
R. Fujikawa
H. Hoshino
Kazuhiko Kuwahara
Norihiko Ikeda
Satoshi Shiono
J. Soh
Y. Ohde
Yasuhiro Tsutani
Medicine